Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.

Publication ,  Journal Article
Trachtman, H; Hainer, JW; Sugg, J; Teng, R; Sorof, JM; Radcliffe, J; Candesartan in Children with Hypertension (CINCH) Investigators,
Published in: J Clin Hypertens (Greenwich)
October 2008

This 4-week randomized, double blind, placebo-controlled study (N=240), 1-year open label trial (N=233), and single-dose pharmacokinetic study (N=22) evaluated candesartan cilexetil (3 doses) in hypertensive children aged 6 to 17 years. Seventy-one percent were 12 years of age or older, 71% were male, and 47% were black. Systolic (SBP)/diastolic (DBP) blood pressure declined 8.6/4.8-11.2/8.0 mm Hg with candesartan and 3.7/1.8 mm Hg with placebo (P<.01 compared to placebo for SBP and for the mid and high doses for DBP; placebo-corrected 4.9/3.0-7.5/6.2 mm Hg). The slopes for dose were not, however, different from zero (P>.05). The response rate (SBP and DBP <95th percentile) after 1 year was 53%. The pharmacokinetic profiles in 6- to 12- and 12- to 17-year-olds were similar and were comparable to adults. Eight candesartan patients discontinued treatment because of an adverse event. Candesartan is an effective, well-tolerated antihypertensive agent for children aged 6 to 17 years and has a pharmacokinetic profile that is similar to that in adults.

Duke Scholars

Published In

J Clin Hypertens (Greenwich)

DOI

ISSN

1524-6175

Publication Date

October 2008

Volume

10

Issue

10

Start / End Page

743 / 750

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tetrazoles
  • Male
  • Hypertension
  • Humans
  • Female
  • Drug Administration Schedule
  • Double-Blind Method
  • Child
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Trachtman, H., Hainer, J. W., Sugg, J., Teng, R., Sorof, J. M., Radcliffe, J., & Candesartan in Children with Hypertension (CINCH) Investigators, . (2008). Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich), 10(10), 743–750. https://doi.org/10.1111/j.1751-7176.2008.00022.x
Trachtman, Howard, James W. Hainer, Jennifer Sugg, Renli Teng, Jonathan M. Sorof, Jerilynn Radcliffe, and Jerilynn Candesartan in Children with Hypertension (CINCH) Investigators. “Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.J Clin Hypertens (Greenwich) 10, no. 10 (October 2008): 743–50. https://doi.org/10.1111/j.1751-7176.2008.00022.x.
Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J, et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich). 2008 Oct;10(10):743–50.
Trachtman, Howard, et al. “Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.J Clin Hypertens (Greenwich), vol. 10, no. 10, Oct. 2008, pp. 743–50. Pubmed, doi:10.1111/j.1751-7176.2008.00022.x.
Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J, Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich). 2008 Oct;10(10):743–750.

Published In

J Clin Hypertens (Greenwich)

DOI

ISSN

1524-6175

Publication Date

October 2008

Volume

10

Issue

10

Start / End Page

743 / 750

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tetrazoles
  • Male
  • Hypertension
  • Humans
  • Female
  • Drug Administration Schedule
  • Double-Blind Method
  • Child
  • Cardiovascular System & Hematology